Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, and distribution/supply of diagnostic equipment for different diagnostic healthcare needs.
The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges.
The company’s key manufacturing segments include indigenous manufacturing of reagents (Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Others [POC Devices & Rapid Tests]) and supplying/manufacturing of in-vitro diagnostics (IVD) and Pathology equipment & devices.
As of December 31, 2025, the total annual capacity was about 1.4 million kits (Haematology, Clinical Chemistry, Rapid/Elisa) and 1,200 Selectra Machines.
As of March 31, 2026, the manufacturing teams include 126 employees and 223 third-party workers collaborating with R&D, supply chain, and external partners to meet benchmarks.
Competitive Strengths:
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 561.34 | 455.49 | 339.25 | 251.58 |
| Total Income | 236.50 | 322.58 | 206.45 | 184.81 |
| Profit After Tax | 38.69 | 28.13 | 34.44 | 32.10 |
| EBITDA | 64.23 | 71.32 | 37.63 | 32.98 |
| NET Worth | -0.04 | 189.95 | 161.81 | 127.37 |
| Reserves and Surplus | 2,12,88,920.00 | 188.37 | 160.24 | 125.79 |
| Total Borrowing | 243.85 | 164.95 | 96.91 | 73.65 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | To meet working capital requirements | 93.50 |
| 2 | Repayment of certain borrowing availed by the Company, in part or full | 90.00 |
| 3 | General Corporate Purposes | |
| Total | 183.50 |
| KPI | Dec 31, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 16.88% | 17.66% |
| ROCE | 13.32% | 23.74% |
| Debt/Equity | 1.06 | 0.87 |
| RoNW | 16.88% | 23.74% |
| PAT Margin | 16.65% | 8.97% |
| EBITDA Margin | 27.64% | 22.73% |
| IPO Date | 21 to 25 May, 2026 |
| Listing Date | Fri, May 29, 2026T |
| Face Value | ₹10 per share |
| Price Band | ₹326 to ₹343 |
| Lot Size | 400 Shares |
| Sale Type | Fresh capital only |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Total Issue Size | 62,53,200 shares (agg. up to ₹214 Cr) |
| Reserved for Market Maker |
3,13,200 shares
(agg. up to ₹11 Cr) |
| Fresh Issue (Ex Market Maker) | 59,40,000 shares (agg. up to ₹204 Cr) |
| Net Offered to Public | 59,40,000 shares (agg. up to ₹204 Cr) |
| Share Holding Pre Issue | 1,70,74,999 shares |
| Share Holding Post Issue | 2,33,28,199 shares |
As per our analysis and Based on the information we have, this is the output.
Allah knows best.
If you find this result mistaken or questionable, let us know via email at info (@) halalstock.in
The IPO dashboard offers insights on the Latest Current & Upcoming IPOs in BSE & NSE. It also evaluates IPOs for Shariah compliance, ensuring alignment with Islamic principles for ethical investment choices.
Last Updated on May 21, 2026 Q-Line Biotech Ltd. IPO Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of
Last Updated on May 21, 2026 Autofurnish Ltd. IPO Incorporated in May 2015, Autofurnish Ltd is engaged in manufacturing and trading automotive accessories.The company mainly operates in the B2B segment,
Last Updated on May 20, 2026 Bio Medica Laboratories Ltd. IPO Incorporated in August 2015, Bio Medica Laboratories specialises in manufacturing pharmaceutical parenteral formulations, producing a wide range of ethical
You can contribute as little as
100, 200, 500 & so…
every bit counts.
